Comparison of the Performance of Aptima HIV-1 Quant Dx Assay with Abbott RealTime HIV Assay for Viral Load Monitoring Using Plasma and Dried Blood Spots Collected in Kenya

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Aug 22

PMID 35994447

Authors

Matilu Mwau

Sven Schaffer

Humphrey Kimani

Purity Kasiano

Francis Ogolla

Elizabeth Ajema

Scriven Adoyo

Ednah Nyairo

Norah Saleri

Sangeetha Vijaysri Nair

Affiliations

Soon will be listed here.

Abstract

Introduction: HIV-1 viral Load (VL) testing is recommended for the monitoring of antiretroviral treatment. Dried Blood Spots (DBS) are an effective sample type in resource limited settings, where safe phlebotomy and reliable shipping are hard to guarantee. In HIV high burden countries, high throughput assays can improve access to testing services. The Hologic Aptima HIV-1 Quant Dx Assay (Aptima Assay) is a high throughput assay that runs on the CE-IVD approved Panther platform. The objectives of this study were to assess the performance characteristics of Aptima for VL monitoring using plasma and venous DBS specimens and to determine the stability of HIV-1 RNA in DBS.

Materials And Methods: This was a cross-sectional study of 2227 HIV infected adults visiting health facilities in Nairobi and Busia, Kenya. Each provided a venous blood sample; plasma was prepared from 1312 samples while paired DBS samples and plasma were prepared from the remaining 915 samples. The agreement between the Aptima assay and the Abbott RealTime HIV-1 Assay (Abbott RT) was analysed by comparing the HIV-1 VL in both assays at the medical decision point of 1000 copies/mL. To assess stability of HIV-1 RNA in DBS, VL in DBS spotted on day 0 were compared with that from the same DBS card after 21 days of storage at room temperature.

Results: Overall, 436 plasma samples had quantifiable results in both Aptima and Abbott RT. The agreement between the two assays at 1000 copies/mL was 97.48% with a Pearson's correlation coefficient (r) of 0.9589 and gave a mean bias of 0.33 log copies/mL on Bland-Altman analysis. For fresh DBS, the agreement in both assays was 94.64% at 1000 copies/mL, with an r of 0.8692 and a mean bias of 0.35 log copies/mL. The overall agreement between DBS tested in Aptima on day 0 versus day 21 was 95.71%, with a mean bias of -0.154.

Conclusion: The Aptima HIV-1 Quant Dx assay is an accurate test for VL monitoring of HIV-1 using DBS and plasma sample types in Kenya.

References

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

Mor O, Gozlan Y, Wax M, Mileguir F, Rakovsky A, Noy B . Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load. J Clin Microbiol. 2015; 53(11):3458-65. PMC: 4609691. DOI: 10.1128/JCM.01806-15. View

Sahoo M, Varghese V, White E, Winslow M, Katzenstein D, Shafer R . Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots. J Clin Microbiol. 2016; 54(10):2597-601. PMC: 5035416. DOI: 10.1128/JCM.01569-16. View

Amendola A, Pisciotta M, Aleo L, Ferraioli V, Angeletti C, Capobianchi M . Evaluation of the Aptima(®) HIV-1 Quant Dx assay for HIV-1 RNA viral load detection and quantitation in plasma of HIV-1-infected individuals: A comparison with Abbott RealTime HIV-1 assay. J Med Virol. 2016; 88(9):1535-44. PMC: 6585778. DOI: 10.1002/jmv.24493. View

Sam S, Kurpewski J, Cu-Uvin S, Caliendo A . Evaluation of Performance Characteristics of the Aptima HIV-1 Quant Dx Assay for Detection and Quantitation of Human Immunodeficiency Virus Type 1 in Plasma and Cervicovaginal Lavage Samples. J Clin Microbiol. 2016; 54(4):1036-41. PMC: 4809915. DOI: 10.1128/JCM.03289-15. View

Schonning K, Johansen K, Landt B, Benfield T, Westh H . Comparison of the Hologic Aptima HIV-1 Quant Dx Assay to the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 for the quantification of HIV-1 RNA in plasma samples. J Clin Virol. 2017; 92:14-19. DOI: 10.1016/j.jcv.2017.05.006. View

Rutherford G, Anglemyer A, Easterbrook P, Horvath T, Vitoria M, Penazzato M . Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS. 2014; 28 Suppl 2:S161-9. DOI: 10.1097/QAD.0000000000000236. View

Yek C, Massanella M, Peling T, Lednovich K, Nair S, Worlock A . Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. J Clin Microbiol. 2017; 55(8):2544-2553. PMC: 5527433. DOI: 10.1128/JCM.00425-17. View

Nair S, Kim H, Fortunko J, Foote T, Peling T, Tran C . Aptima HIV-1 Quant Dx--A fully automated assay for both diagnosis and quantification of HIV-1. J Clin Virol. 2016; 77:46-54. DOI: 10.1016/j.jcv.2016.02.002. View

10.

Wiesmann F, Ehret R, Naeth G, Daumer M, Fuhrmann J, Kaiser R . Multicenter Evaluation of Two Next-Generation HIV-1 Quantitation Assays, Aptima Quant Dx and Cobas 6800, in Comparison to the RealTie HIV-1 Reference Assay. J Clin Microbiol. 2018; 56(10). PMC: 6156314. DOI: 10.1128/JCM.00292-18. View

11.

Monleau M, Butel C, Delaporte E, Boillot F, Peeters M . Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. J Antimicrob Chemother. 2010; 65(8):1562-6. DOI: 10.1093/jac/dkq205. View

12.

Saune K, Raymond S, Boineau J, Pasquier C, Izopet J . Detection and quantification of HIV-1 RNA with a fully automated transcription-mediated-amplification assay. J Clin Virol. 2016; 84:70-73. DOI: 10.1016/j.jcv.2016.09.002. View

13.

Hatzakis A, Papachristou H, Nair S, Fortunko J, Foote T, Kim H . Analytical characteristics and comparative evaluation of Aptima HIV-1 Quant Dx assay with Ampliprep/COBAS TaqMan HIV-1 test v2.0. Virol J. 2016; 13(1):176. PMC: 5073876. DOI: 10.1186/s12985-016-0627-y. View

14.

Schalasta G, Borner A, Speicher A, Enders M . Comparative evaluation of the Aptima HIV-1 Quant Dx assay and COBAS TaqMan HIV-1 v2.0 assay using the Roche High Pure System for the quantification of HIV-1 RNA in plasma. Clin Chem Lab Med. 2015; 54(3):493-9. DOI: 10.1515/cclm-2015-0522. View

15.

Barth R, Schim van der Loeff M, Schuurman R, Hoepelman A, Wensing A . Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010; 10(3):155-66. DOI: 10.1016/S1473-3099(09)70328-7. View

16.

Manak M, Hack H, Nair S, Worlock A, Malia J, Peel S . Evaluation of Hologic Aptima HIV-1 Quant Dx Assay on the Panther System on HIV Subtypes. J Clin Microbiol. 2016; 54(10):2575-81. PMC: 5035401. DOI: 10.1128/JCM.01350-16. View

17.

Sloma C, Germer J, Gerads T, Mandrekar J, Mitchell P, Yao J . Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol. 2009; 47(4):889-95. PMC: 2668302. DOI: 10.1128/JCM.02231-08. View

18.

Gounder K, Oyaro M, Padayachi N, Zulu T, de Oliveira T, Wylie J . Complex Subtype Diversity of HIV-1 Among Drug Users in Major Kenyan Cities. AIDS Res Hum Retroviruses. 2017; 33(5):500-510. PMC: 5439455. DOI: 10.1089/AID.2016.0321. View

19.

Bbosa N, Kaleebu P, Ssemwanga D . HIV subtype diversity worldwide. Curr Opin HIV AIDS. 2019; 14(3):153-160. DOI: 10.1097/COH.0000000000000534. View

20.

Hopkins M, Hau S, Tiernan C, Papadimitropoulos A, Chawla A, Beloukas A . Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays. J Clin Virol. 2015; 69:56-62. DOI: 10.1016/j.jcv.2015.05.020. View